Galvokimig for Bronchiectasis

(ATMOS Trial)

This trial tests galvokimig to determine if it can delay lung flare-ups in individuals with non-cystic fibrosis bronchiectasis, a condition causing persistent coughing and mucus. Participants will receive varying doses of galvokimig or a placebo (a pill with no medicine) to compare effects. It suits those who have experienced at least two significant lung flare-ups in the past year and currently produce mucus regularly. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to important early-stage findings.

A previous study tested Galvokimig on people with atopic dermatitis, a skin condition that causes itchy and inflamed skin. The safety results were consistent, with no unexpected problems reported, suggesting that Galvokimig was generally well-tolerated by participants. However, larger studies are needed to fully confirm its safety. Galvokimig is currently in an early testing phase, so information on its safety for treating non-cystic fibrosis bronchiectasis—a lung condition that causes a persistent cough and mucus production—remains limited.¹²³⁴⁵

Galvokimig is unique because it potentially offers a new approach to treating bronchiectasis, a condition often managed with antibiotics and airway clearance techniques. Unlike standard treatments, Galvokimig is designed to target the underlying inflammation in the airways more directly, which could reduce reliance on antibiotics and improve lung function. Researchers are particularly excited about its novel mechanism of action, which might offer better control over symptoms and fewer side effects compared to existing therapies.

Studies have shown that galvokimig, a new antibody-based treatment, targets key proteins involved in inflammation, such as IL-13, IL-17A, and IL-17F. These proteins play a role in conditions like non-cystic fibrosis bronchiectasis (NCFB), which inflames the airways. Previous research on other conditions, such as atopic dermatitis, demonstrated that over 60% of patients experienced significant symptom improvement with galvokimig. Although data specifically for NCFB is limited, the mechanism of galvokimig suggests it might reduce airway inflammation and improve symptoms in NCFB. Researchers continue to study the treatment, which shows promise based on its effects in related conditions. Participants in this trial will receive varying doses of galvokimig or a placebo to assess its effectiveness and safety in treating NCFB.²⁴⁵⁶⁷